Institutional members access full text with Ovid®

Share this article on:

Sexual Dysfunction in 156 Ambulatory HIV-Infected Men Receiving Highly Active Antiretroviral Therapy Combinations With and Without Protease Inhibitors

Lallemand, F.; Salhi, Y.; Linard, F.; Giami, A.; Rozenbaum, W.
JAIDS Journal of Acquired Immune Deficiency Syndromes: June 1st, 2002
doi: 10.1097/01.QAI.0000014715.20554.90
Brief Report: PDF Only

We conducted a cross-sectional study of 156 ambulatory HIV-infected homosexual or bisexual men to assess and compare the prevalence and characteristics of sexual dysfunction according to treatment combinations (group A, protease inhibitor [PI] treatment; group B, no PI treatment; and C, PI treatment interrupted >1 month previously). The study was based on a self-administered 163-item questionnaire that included a French translation of the International Index of Erectile Function, five sections of the Derogatis Sexual Functioning Inventory, and open questions. Data analysis was performed using Mann-Whitney and Kruskal-Wallis H nonparametric tests (quantitative values) and χ2 tests (qualitative values) using SPSS software (SPSS, Chicago, IL, U.S.A.). One hundred fifty-six patients completed the study. The median age ± SD of the patients was 40.5 ± 7.7 years, and the median CD4+ cell count ± SD was 415 ± 236/mm3. One hundred eleven (71%) of 156 patients reported some degree of sexual dysfunction since the beginning of their treatment (65 [71%] of 91 group A patients; 15 [65%] of 23 group B patients; and 31 [74%] of 42 group C patients), with no significant difference among the groups. Of the 111 patients, 99 (89%) reported decrease or loss of libido, 76 (68%) reported orgasmic perturbation, 96 (86%) reported erectile dysfunction, and 65 (59%) reported ejaculation perturbation, with no significant difference among the three groups. There were no significant differences among the three groups regarding the International Index of Erectile Function and Derogatis Sexual Functioning Inventory scores. These data suggest that PI-based therapy does not seem to increase sexual dysfunction in this patient population.

Address correspondence and reprint requests to Francis Lallemand. MD, Hôpital Tenon, Service de Maladies Infectieuses et Tropicales, rue de la Chine, 75020 Paris, France; e-mail: flallemand@free.fr

Manuscript received October 31, 2001; accepted February 15, 2002.

© 2002 Lippincott Williams & Wilkins, Inc.